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oRIGINAL ARTICLE
Introduction: This study aimed to establish from the published lit-
erature the efficacy of a positron emission tomography (PET)-based 
strategy for the staging of small-cell lung cancer compared to con-
ventional methods, the potential impact on patient management and 
outcomes, and cost implications for the Australian health system.
Methods: EMBASE, Current Contents, PubMed, and oVID, data-
bases were searched using relevant search terms. Reference lists of 
identified studies were examined for additional pertinent papers. 
Literature review identified 22 relevant studies containing data for 
1663 patients. Studies were evaluated regarding the adequacy of 
pathological or clinical correlation of imaging findings. Efficacy of 
PET-staging was analyzed. The Medicare benefits schedule was used 
to compare costs of the two strategies.
Results: Published data confirm that PET staging has a sensitivity 
approaching 100% and specificity exceeding 90%. Data suggest 
that compared to conventional staging, PET can alter management 
(including radiotherapy portal changes) in at least 28% of patients, 
can result in the addition of life-prolonging radiotherapy in 6%, and 
avert unnecessary radiotherapy with associated toxicity in 9%. PET-
based staging costs 1603 Australian dollars (AUD) and conventional 
staging 1610 AUD per patient. An additional 540,354 AUD may be 
saved annually through avoidance of unnecessary radiotherapy.
Conclusions: PET-based staging seems superior to conventional stag-
ing, and can significantly alter patient management particularly with 
regard to the inclusion, omission, and portal design of radiotherapy. The 
initial costs of the two strategies do not seem significantly different. 
PET may ultimately reduce healthcare costs through avoidance of inap-
propriate thoracic radiotherapy. The major advantages of PET-staging 
may, however, lie in averting unnecessary toxicity and in the appropriate 
addition of thoracic radiotherapy with potential survival gains.
Key Words: Staging, Positron emission tomography, Small-cell lung 
cancer.
(J Thorac Oncol. 2012;7: 1015–1020)
Small-cell lung cancer (SCLC) accounts for 15% of all lung cancer presentations. It ranks as the fifth leading cause of 
cancer deaths in the United States.1 Although the tumor, node, 
metastasis staging system is prognostic, clinical management 
is still guided by the two-tiered staging system first proposed 
by the Veterans Administration Lung Study Group and later 
modified by the International Association for the Study of Lung 
Cancer (IASLC).2 The IASLC modification provides superior 
prognostication.3 This system divides patients into those with 
limited disease (LD) or extensive disease (ED). LD includes 
disease limited to one hemithorax including contralateral medi-
astinal and supraclavicular nodes, and also includes ipsilateral 
pleural effusion independent of cytological findings.2 Patients 
with LD have a median survival of 23 to 27 months,4,5 com-
pared to 10 to 12 months for those with ED.6–8 State-of-the-
art management for fit patients with LD involves concurrent 
chemoradiation5 optimally delivered in twice-daily fractions,4 
although the value of twice-daily irradiation versus high-dose 
daily radiotherapy is undefined and the subject of ongoing tri-
als (CALGB 30610/RToG 0538 and CoNVERT). Patients 
with extensive stage SCLC are treated with palliative chemo-
therapy and do not generally receive thoracic radiotherapy.
Accurate staging is thus paramount to ensure that LD 
patients are not denied life-prolonging thoracic radiotherapy 
and conversely, that ED patients are spared the toxicity of con-
current thoracic radiotherapy, which confers them no benefit. 
The distinction between the limited and extensive stages is also 
important when considering the merits and dose of prophylac-
tic cranial radiotherapy. Doubling time is 33 days, therefore 
rapid staging and initiation of treatment is paramount.9
Fluorodeoxyglucose (FDG) positron emission tomogra-
phy (PET) has been widely embraced as part of the routine 
workup for non–small-cell lung cancer (NSCLC), and is reim-
bursed by national health funding in Australia and the United 
Kingdom along with many other countries. In contrast, FDG-
PET has not yet been widely incorporated into the staging of 
SCLC. A literature review was thus undertaken to establish the 
efficacy of PET in this setting before considering its cost impli-
cations compared to a conventional workup.
METHODS
Literature Review
EMBASE, Current Contents, MEDLINE, and oVID 
databases were searched using the Boolean operators “PET,” 
“positron emission tomography,” and “small cell lung cancer.” 
The reference lists of identified papers were examined to 
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identify further studies of relevance. The literature review was 
confined to English-language papers. Each study was assessed 
with the inclusion and exclusion criteria below. The results 
presented are weighted averages across all studies propor-
tional to the patient numbers contributed by each study rela-
tive to the total number for each endpoint.
Selection Criteria
Eligible studies were those that included patients with 
cyto- or histologically confirmed SCLC or mixed SCLC/
NSCLC, who underwent PET as part of initial workup for 
SCLC (in one study, PET was performed 1–11 days after treat-
ment commenced in 33% of the patients).10 For studies in which 
PET was performed both for staging and response assessment, 
only data relating to initial staging were considered. only data 
that were explicitly stated or that could unambiguously be cal-
culated from information provided were incorporated into the 
present results. A single study used both fluorine-18 fluoro-
deoxyglucose ([18F] FDG), and 3,4-dihydroxy-6-18F-fluoro-
phenylalanine ([18F]FDoPA) as radiotracers;11 however, only 
results for FDG-PET are included in the present review.
Cost Analysis
Calculations were based on 1091 new cases of SCLC 
per annum. This figure was derived from averaged annual 
Australian SCLC incidence figures for 2001 to 2005 (Mark 
Short, Australian Institute of Health and Welfare, personal 
communication). Costs were based on the Australian Medicare 
Benefits Schedule of July 2010. They thus reflect costs to soci-
ety from the government perspective. Although these values 
might not accurately reflect the exact dollar cost of each inter-
vention to society, they do provide a reasonable indication of 
such costs, and more importantly allow comparisons within 
a single healthcare system. Costs for investigations are pre-
sented in Australian Dollars and are enumerated in Table 1.
The cost of conventional staging included a computed 
tomography (CT) brain, CT chest, a separately obtained CT 
abdomen and pelvis, bone scan, liver-function tests, and 
serum biochemistry.1 The cost of a CT chest (Table 1. item 
56307) was considered separately from a CT abdomen/pelvis 
(item 56507), rather than a combined CT chest, abdomen, and 
pelvis as a single investigation (item 56807). This is because 
almost all patients will have received a CT chest before diag-
nosis is formally established and staging is undertaken. Thus 
a CT chest is usually obtained separately from CT abdomen/
pelvis, and cost is accrued from two separate attendances and 
investigations. Identical blood tests are required for both stag-
ing approaches. These are therefore cost neutral and were not 
considered further.
The cost of PET-based staging included a CT brain, CT 
chest, PET scan, and blood tests. PET appears superior to bone 
scan for detecting bone metastases even though it does not image 
below the knees.10,12–15 PET thus negates the need for bone scan 
and CT abdomen/pelvis, and thus may possibly be quicker to 
execute depending on local resources. A brain CT or magnetic 
resonance imaging (MRI) is still required for staging as PET has 
only 45% to 50% sensitivity for brain metastases.12,15 Although 
MRI is more sensitive than CT for the detection of brain metas-
tases, we chose CT as our staging strategy for cost analysis. 
This is because CT brain is more widely accessible than MRI 
for this purpose and is almost exclusively the neuro-imaging 
modality employed in the presently reviewed literature.
RESULTS
Utility of PET for Initial Staging of SCLC
Twenty-two relevant studies containing data on 1663 
patients were identified. Data for 1082 of these patients are 
from the National oncologic PET Registry, which provide 
information on the impact of PET on altering intended man-
agement only. These results are tabulated in Table 2.
Eleven of 22 studies clearly employed adequate clini-
cal or pathological correlation to confirm or refute their 
imaging findings.10,12,15–23 Three studies had incomplete clini-
copathological correlation of their imaging findings (43%, 
83%, and 87%, respectively).14,24,25 The adequacy of clinico-
pathological correlation could not be definitively assessed in 
six more studies, mainly because of the unspecified length of 
clinical follow-up.13,26–30 Two studies were inadequate in terms 
of clinicopathological verification of imaging findings.11,31 
Eight studies were prospective, and 12,13,18,20,23,27,31 14 were 
retrospective.10,14–17,19,21,22,24–26,28–30
Published data confirm that PET-based staging has a 
sensitivity approaching 100% and specificity exceeding 90%. 
CT-PET improved specificity compared to PET alone (100% 
versus 83%) in the only (prospective) study reporting on this 
outcome.23 Data suggest that compared to conventional stag-
ing, PET can alter management (including radiotherapy portal 
changes) in 28% of the patients. If studies omitting data on 
radiotherapy portal changes are included, PET alters manage-
ment in 38% of patients. This is because of the large impact 
of the National oncologic PET Registry study with 1082 
patients.31 PET can result in the addition of potentially life-
prolonging radiotherapy in 6%, and can avert unnecessary 
radiotherapy with associated toxicity in 9%. For patients with 
LD, PET can alter radiotherapy portals in 23%. Seven studies 
specifically analyzed individual discordant sites as determined 
by PET versus conventional staging (Table 3).
Cost Analysis
A PET-based staging strategy costs 1603 AUD per 
patient (CT brain + CT chest + PET scan). Conventional 
TABLE 1. Cost per Investigation According to Medicare 
Benefits Schedule (July 2010)
Investigation Item Cost (AUD)
PET-CT 61529 953
Bone scan 61421 480
CT chest, abdomen, and pelvis 56807 560
CT chest alone 56307 400
CT abdomen and pelvis 56507 480
CT brain 56007 250
PET, positron emission tomography; CT, computed tomography.
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TABLE 2. Utility of FDG-PET in SCLC Staging
RT Portal 
Change 
% (LD 
patients)
Required 
RT (%)
Averted 
RT (%)
% True 
Upstaged
% True 
Downstaged
Falsely 
Upstaged 
(%)
Falsely 
Downstaged 
(%) Specificity Sensitivity
PET or 
PET-CT
Adequate 
Follow 
Up (F/U) 
Correlation Pt No Reference
12a — 4 8 8 3 0 1b 92–98 100 PET yes 120 Brink  
et al.12
16a — 12 4 4 12 2 4bc — 100 PET yes 51 Vinjamuri  
et al.15 
41a — — — — — — — — — Unspecified no 1082 (Hillner  
et al.31
47 25 0 33 33 0 0 0 — 100 PET yes 15 Blum et al.22
22d 14 only LD 8 8 only LD 2 only LD — — PET and 
PET-CT
yes 63 Niho et al.10 
26e 12 13 7e 9 17 — — — — PET and 
PET-CT
yes 46 Azad et al.16
37 33 4 
(surgery)
13 13 4 0 0 — — PET and 
PET-CT
Equivocal 24 Kamel  
et al.26
— 29 only LD 4 8 only LD 4 only LD 96 100 PET Equivocal  
? length F/U
24 Bradley  
et al.27
— 30f only LD — — only LD — only LD — — PET-CT yes 60 van Loon  
et al.20
— 24f only LD — — only LD — only LD — — PET-CT Unable to 
assess
21 van Loon  
et al.29
— — — — 10 3 equivocal 0 3 PET CTc,
13 PET
100 PET- 
CT
83 PET
93 PET
93 PET
PET-CT yes 29 Fischer  
et al.23
— — 0 0 0 0 0 0 — 100 PET Equivocal  
? length F/U
18 Kut et al.13
— — — — 42 8 0 0 — 100 PET Equivocal 
F/U in only 
83%
12 Arslan  
et al.24
— — 0 27 19g 0 0 0 — — PET Equivocal 
only in 43%
26 Schumacher 
B et al.14 
— — — — — — — — 100 100 PET Equivocal 
Histo in 
≥86%  
? length F/U 
in others
7 Hauber  
et al.25
— — 0 0 0 0 0 0 — 100 PET yes 8 Pandit  
et al.17 
— — — — 11 5 0 0 — — PET yes 18 Chin et al.18
— — 4 4 4 4 0 0 — 100 PET yes 25 Shen et al.19
— — — — — — — — — 100 PET Unable to 
assess
3 Zhao et al.28
— — — — — — — — — 100 PET Unable to 
assess
5 Sazon  
et al.30
— — — — — — — — — 100 PET yes 2 Saunders  
et al.21
— — — — 0 0 0 0 — — PET No 4 Jacob  
et al.11
Weighted average
28 23 6 9 9 6
aExcluding radiation portal alterations.
bReflecting known insensitivity for brain metastases.
cMissed liver metastases.
dDoes not include potential for downstaging.
eWould be 33% but some staged patients were unfit for, or refused treatment. If all staged patients were fit for treatment, 9% would avoid RT.
fStudy specifically designed to answer this question.
gFurther 8% unconfirmed.
PET, positron emission tomography; FDG, Fluorodeoxyglucose; SCLC, Small-cell lung cancer; RT; radiation therapy; CT, computed tomography; LD, limited disease.
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staging costs 1610 AUD (CT chest + CT brain + CT abdomen 
and pelvis + bone scan).
Based on 1091 new cases per annum, if 6% of patients 
are downstaged by PET, and are all assumed fit enough to 
receive concurrent thoracic radiotherapy, which improves 
survival by 12 months on average and costs 5503 AUD per 
patient, an extra 360,226 AUD would be incurred per annum. 
However, this could be offset by the 540,354 AUD saved annu-
ally through the avoidance of unnecessary radiotherapy in the 
9% of patients who are upstaged to ED. overall, this repre-
sents a modest cost saving of 2752 AUD per life-year gained.
DISCUSSION
As yet there are no randomized data for PET in the 
staging of SCLC, and less data exist overall than for NSCLC. 
However, data does exist from prospective studies with 
good clinicopathological correlation of PET findings in 227 
patients.12,18,20,23 In addition, retrospective data with good 
clinicopathological confirmation are also available from 
seven studies comprising 210 patients.10,15–17,19,21,22 The data 
appear consistent across the literature, suggesting that SCLC 
is highly PET avid. PET staging appears superior to con-
ventional methods in terms of demonstrating the primary 
tumor and undetected secondaries (because of improved 
sensitivity). PET also appears able to better distinguish false 
metastatic findings compared to CT (improved specificity). It 
should be noted that PET specificity depends on the preva-
lence of other PET-avid disease in the population being staged 
(e.g., tuberculosis, sarcoidosis, and histoplasmosis), and may 
differ in some populations from the 90-plus percent reported 
in the literature. However, PET specificity in the context of 
SCLC would be similar to that for NSCLC in the same popu-
lation. PET also seems superior in detecting involved medi-
astinal and supraclavicular lymph nodes. This has important 
implications for radiotherapy portal design, efficacy, and tox-
icity.20 Apart from a minority of studies showing no difference 
between staging strategies,11,17,28 the literature consistently 
demonstrates PET staging as more accurate than conventional 
methods. Importantly, no study showed conventional imaging 
to be superior to PET in the initial workup of SCLC. Studies 
evaluating discrepancies between PET-based staging and con-
ventional methods on a site-by-site basis similarly found PET 
consistently more accurate.
However, PET does have limitations that are important 
to appreciate. Although superior to bone scans for detect-
ing bone metastases,10,12–15 PET is inferior to CT and MRI 
in detecting brain metastases from SCLC, with a sensitivity 
of just 46% to 50%.12,15 PET is also limited in sensitivity for 
mucosal and urogenital-tract lesions, and care should be taken 
in its interpretation in these areas. Pericardial and pleural 
effusions are inadequately assessed by PET,13 but accurately 
assessed by PET-CT. PET infrequently missed liver secondar-
ies in 0.9% of patients. Many of the reported inaccuracies of 
PET in the articles reviewed relate to the known insensitiv-
ity of PET for brain metastases, mucosal lesions, and effu-
sions. Some of these inaccuracies may have been averted by 
the coregistration of PET images with CT,23 and would thus be 
overcome by modern scanners that almost universally incor-
porate a co-mounted CT scanner for image coregistration and 
attenuation correction. Such technology maximizes the syn-
ergism and cross sensitivity/specificity of both PET and CT. 
Insensitivity of FDG-PET staging for brain metastases, how-
ever, can only be overcome through the concomitant use of 
contrasted CT brain or MRI.
The reviewed literature suggests that more than a quarter 
of patients could have their management altered through the 
use of PET staging. A significant minority of patients could 
be spared the toxicity of unnecessary thoracic radiotherapy; 
whereas a further minority who would otherwise have missed 
out on concurrent radiotherapy could be correctly identified as 
benefiting from this life-prolonging treatment. Furthermore, 
PET could alter radiotherapy portals in about a quarter of LD 
patients. Surgical series confirm that CT tends to underesti-
mate lymph-node involvement in the mediastinum and supra-
clavicular areas in SCLC.32,33 PET appears superior to CT in 
this regard,20 and its use might therefore improve the efficacy of 
radiotherapy and/or reduce its toxicity. When performed in addi-
tion to standard investigations, PET frequently detects metastatic 
foci not detected by other imaging modalities.11–14,17,22,23,25–27 
This does not often change patient management, however, 
because in the majority of such cases, ED has already been 
diagnosed.
The literature on PET-staging for SCLC reviewed here 
is subject to substantial limitations. Although complete his-
tological confirmation of all PET findings would be the gold 
standard, this is neither practical nor is it ethically clear. 
Consequently, most studies rely on a combination of histologi-
cal confirmation together with clinical follow-up of suspected 
sites of disease, interpreting their natural course or response to 
treatment as proof of their true nature. This problem is shared 
by NSCLC PET studies. A further limitation is the lack of 
randomized data. However, as previously noted, a significant 
volume of good quality nonrandomized data, both prospective 
and retrospective, have now been accumulated. The available 
data seem consistent. Not every study reported data for each 
endpoint of interest. Thus, many findings of this review are 
based on the results of only a few studies.
TABLE 3. Evaluation of Discordant Sites
% PET Correct
% Conventional 
Correct % Indeterminate Reference
67 7 26 Azad et al.16
33 0 66 Chin et al.18
94 0 6 Niho et al.10
79 14 7 Blum et al.22
60 20a 20 Kut et al.13
65 18 18 Schumacher 
et al.14
72 15b 12 Brink et al.12
aDetection of pericardial effusion accounts for all these cases of CT superiority.
bDetection of brain metastases accounts for 70% of these cases of CT superiority.
CT, computed tomography.
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It is acknowledged that the present cost analysis is also 
subject to limitations. The cost analysis is by no means meant to 
be exhaustively detailed; rather, it is illustrative of the relative 
costs of the two staging strategies. Micro-costings of the inves-
tigations and treatment were not performed. Rather, Medicare 
reimbursement amounts were used for calculations. These 
Medicare figures are, however, used by government health-
care funding committees for cost-effectiveness calculations 
(Dale Brooker, Department of Health and Ageing, personal 
communication), and may therefore be regarded as reflect-
ing true costs with a high degree of accuracy. Conventional 
cost-effectiveness methodology often employs a decision tree 
analysis. However, for the current study, a decision tree incor-
porating the proportion of patients categorized as ED after 
each successive conventional staging procedure was felt not 
to be reflective of clinical reality where staging investigations 
are often ordered together. Furthermore, reliable data about 
such staging endpoints is not available to populate the tree. 
Hence we adopted a more straightforward method of costing 
each approach and limiting the analysis to staging and initial 
treatment only. In any case, second-line treatment and its asso-
ciated costs are likely to be similar for progressive disease 
regardless of initial staging and treatment strategy.
In a Danish study, the costs of staging and primary treat-
ment were compared using PET/CT versus standard staging. 
Patients were admitted for all staging investigations—the 
duration of which was shorter with PET/CT. No significant 
cost difference was found.23
CONCLUSIONS
The true improvement offered by PET in staging SCLC 
is difficult to define because of variations in and limitations 
of study designs, the lack of randomized data, and the lack of 
complete histological corroboration in most studies. However, 
it is fair to note that the majority of studies have reported ade-
quate correlation of PET findings with clinical or pathologi-
cal outcomes, that results appear consistent across studies and 
patient populations, that where discrepancies between CT and 
PET have been investigated, PET has consistently proved to be 
more accurate, and that substantial data are accumulating in 
favor of PET. A successful randomized trial is unlikely given 
the prohibitive numbers of patients required to demonstrate 
differences in clinically meaningful endpoints. Within such 
context and limitations, the current literature suggests that PET-
based staging appears superior to conventional staging and can 
significantly alter patient management, particularly with regard 
to the inclusion, omission, and portal design of radiotherapy. 
Initial costs of the two strategies do not seem significantly dif-
ferent, provided no doubling up of investigations occurs. The 
main advantages of PET-staging may however lie in averting 
unnecessary toxicity and in the appropriate addition of thoracic 
radiotherapy with potential survival gains.
REFERENCES
 1. Argiris A Murren JR. Staging and clinical prognostic factors for small-
cell lung cancer. Cancer J 2001;7:437–447.
 2. Stahel R, Ginsberg RJ, Havemann K, et al. Staging and prognostic factors in 
small cell lung cancer: a consensus report. Lung Cancer 1989;5:119–126.
 3. Micke P, Faldum A, Metz T, et al. Staging small cell lung cancer: Veterans 
Administration Lung Study Group versus International Association for 
the Study of Lung Cancer–what limits limited disease? Lung Cancer 
2002;37:271–276.
 4. Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with 
once-daily thoracic radiotherapy in limited small-cell lung cancer 
treated concurrently with cisplatin and etoposide. N Engl J Med 
1999;340:265–271.
 5. Takada M, Fukuoka M, Kawahara M, et al. Phase III study of concurrent 
versus sequential thoracic radiotherapy in combination with cisplatin and 
etoposide for limited-stage small-cell lung cancer: results of the Japan 
Clinical oncology Group Study 9104. J Clin Oncol 2002;20:3054–3060.
 6. Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase III trial 
comparing irinotecan/cisplatin with etoposide/cisplatin in patients with 
previously untreated extensive-stage disease small-cell lung cancer. 
J Clin Oncol 2006;24:2038–2043.
 7. Heigener DF, Manegold C, Jäger E, Saal JG, Zuna I, Gatzemeier U. 
Multicenter randomized open-label phase III study comparing efficacy, 
safety, and tolerability of conventional carboplatin plus etoposide 
versus dose-intensified carboplatin plus etoposide plus lenograstim in 
small-cell lung cancer in “extensive disease” stage. Am J Clin Oncol 
2009;32:61–64.
 8. Lara PN Jr, Natale R, Crowley J, et al. Phase III trial of irinotecan/
cisplatin compared with etoposide/cisplatin in extensive-stage small-cell 
lung cancer: clinical and pharmacogenomic results from SWoG S0124. 
J Clin Oncol 2009;27:2530–2535.
 9. Payne D, Naruke T. Manual of clinical oncology. In: RE Pollock, ed. 
Manual of Clinical oncology. New york, Ny: Wiley, 1999:385–405.
10. Niho S, Fujii H, Murakami K, et al. Detection of unsuspected distant 
metastases and/or regional nodes by FDG-PET [corrected] scan in apparent 
limited-disease small-cell lung cancer. Lung Cancer 2007;57:328–333.
11. Jacob T, Grahek D, younsi N, et al. Positron emission tomography with [(18)
F]FDoPA and [(18)F]FDG in the imaging of small cell lung carcinoma: 
preliminary results. Eur J Nucl Med Mol Imaging 2003;30:1266–1269.
12. Brink I, Schumacher T, Mix M, et al. Impact of [18F]FDG-PET on the 
primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging 
2004;31:1614–1620.
13. Kut V, Spies W, Spies S, Gooding W, Argiris A. Staging and monitoring 
of small cell lung cancer using [18F]fluoro-2-deoxy-D-glucose-positron 
emission tomography (FDG-PET). Am J Clin Oncol 2007;30:45–50.
14. Schumacher T, Brink I, Mix M, et al. FDG-PET imaging for the staging and 
follow-up of small cell lung cancer. Eur J Nucl Med 2001;28:483–488.
15. Vinjamuri M, Craig M, Campbell-Fontaine A, Almubarak M, Gupta N, 
Rogers JS. Can positron emission tomography be used as a staging tool 
for small-cell lung cancer? Clin Lung Cancer 2008;9:30–34.
16. Azad A, Chionh F, Scott AM, et al. High impact of 18F-FDG-PET on 
management and prognostic stratification of newly diagnosed small cell 
lung cancer. Mol Imaging Biol 2010;12:443–451.
17. Pandit N, Gonen M, Krug L, Larson SM. Prognostic value of [18F]FDG-
PET imaging in small cell lung cancer. Eur J Nucl Med Mol Imaging 
2003;30:78–84.
18. Chin R Jr, McCain TW, Miller AA, et al. Whole body FDG-PET for the 
evaluation and staging of small cell lung cancer: a preliminary study. 
Lung Cancer 2002;37:1–6.
19. Shen yy, Shiau yC, Wang JJ, Ho ST, Kao CH. Whole-body 18F-2-
deoxyglucose positron emission tomography in primary staging small 
cell lung cancer. Anticancer Res 2002;22(2B):1257–1264.
20. van Loon J, De Ruysscher D, Wanders R, et al. Selective nodal irradiation 
on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: 
a prospective study. Int J Radiat Oncol Biol Phys 2010;77:329–336.
21. Saunders CA, Dussek JE, o’Doherty MJ, Maisey MN. Evaluation 
of fluorine-18-fluorodeoxyglucose whole body positron emission 
tomography imaging in the staging of lung cancer. Ann Thorac Surg 
1999;67:790–797.
22. Blum R, MacManus MP, Rischin D, Michael M, Ball D, Hicks RJ. 
Impact of positron emission tomography on the management of patients 
with small-cell lung cancer: preliminary experience. Am J Clin Oncol 
2004;27:164–171.
23. Fischer BM, Mortensen J, Langer SW, et al. A prospective study of PET/
CT in initial staging of small-cell lung cancer: comparison with CT, bone 
scintigraphy and bone marrow analysis. Ann Oncol 2007;18:338–345.
1020 Copyright © 2012 by the International Association for the Study of Lung Cancer
Ruben et al. Journal of Thoracic Oncology  •  Volume  7, Number 6, June 2012
24. Arslan N, Tuncel M, Kuzhan o, et al. Evaluation of outcome prediction 
and disease extension by quantitative 2-deoxy-2-[18F] fluoro-D-glucose 
with positron emission tomography in patients with small cell lung cancer. 
Ann Nucl Med 2011;25:406–413.
25. Hauber HP, Bohuslavizki KH, Lund CH, Fritscher-Ravens A, Meyer A, 
Pforte A. Positron emission tomography in the staging of small-cell lung 
cancer: a preliminary study. Chest 2001;119:950–954.
26. Kamel EM, Zwahlen D, Wyss MT, Stumpe KD, von Schulthess GK, 
Steinert HC. Whole-body (18)F-FDG PET improves the management of 
patients with small cell lung cancer. J Nucl Med 2003;44:1911–1917.
27. Bradley JD, Dehdashti F, Mintun MA, Govindan R, Trinkaus K, Siegel 
BA. Positron emission tomography in limited-stage small-cell lung 
cancer: a prospective study. J Clin Oncol 2004;22:3248–3254.
28. Zhao DS, Valdivia Ay, Li y, Blaufox MD. 18F-fluorodeoxyglucose 
positron emission tomography in small-cell lung cancer. Semin Nucl Med 
2002;32:272–275.
29. van Loon J, offermann C, Bosmans G, et al. 18FDG-PET based radiation 
planning of mediastinal lymph nodes in limited disease small cell lung 
cancer changes radiotherapy fields: a planning study. Radiother Oncol 
2008;87:49–54.
30. Sazon DA, Santiago SM, Soo Hoo GW, et al. Fluorodeoxyglucose-
positron emission tomography in the detection and staging of lung cancer. 
Am J Respir Crit Care Med 1996;153:417–421.
 31. Hillner BE, Siegel BA, Shields AF, et al. Relationship between cancer 
type and impact of PET and PET/CT on intended management: findings 
of the national oncologic PET registry. J Nucl Med 2008;49:1928–1935.
 32. Sakai M, Ishikawa S, yamamoto T, et al. Preoperative TNM evaluation of 
peripheral clinical stage I small cell lung cancer treated by initial lobectomy with 
adjuvant chemotherapy. Interact Cardiovasc Thorac Surg 2005;4:118–122.
33. Inoue M, Nakagawa K, Fujiwara K, Fukuhara K, yasumitsu T. Results of 
preoperative mediastinoscopy for small cell lung cancer. Ann Thorac Surg 
2000;70:1620–1623.
